Learn languages naturally with fresh, real content!

tap to translate recording

Explore By Region

flag The FDA launched PreCheck on Feb. 1, 2026, to speed drug facility approvals, but four of seven fast-tracked drugs faced delays due to safety issues.

flag The U.S. FDA launched the PreCheck pilot program on February 1, 2026, to accelerate construction and regulatory review of new domestic pharmaceutical facilities, prioritizing critical drugs and innovative designs. flag The two-phase approach includes early FDA engagement during planning and pre-application feedback to streamline approvals. flag Complementing it, the National Priority Voucher Program offers expedited reviews—targeting decisions in one to two months—for vital drugs. flag However, internal documents show at least four of seven fast-tracked drugs faced delays due to safety and efficacy concerns, including a patient death, with some approvals postponed despite initial timelines. flag The FDA maintains its commitment to balancing speed with rigorous safety evaluation.

9 Articles